Alx Oncology Holdings (ALXO) Return on Invested Capital (2020)

Alx Oncology Holdings' (ALXO) quarterly Return on Invested Capital came in at 0.0% in Q4 2020, up 92.39% quarter-over-quarter from 0.0% in Q3 2020.

Alx Oncology Holdings (ALXO) Return on Invested Capital (2020) Analysis & Trends

Alx Oncology Holdings has disclosed Return on Invested Capital across 1 years of filings, most recently posting 0.0% for Q4 2020.

Return on Invested Capital for Q4 2020 came in at 0.0%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was 0.0% (changed N/A YoY), and the FY2022 annual result was 0.0%, changed 0.0% from the prior year.
Return on Invested Capital came in at 0.0% for Q4 2020 at Alx Oncology Holdings, up from 0.0% in the prior quarter.
In the past five years, Return on Invested Capital ranged from a high of 0.0% in Q2 2020 to a low of 0.0% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	0.01%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-0.01%
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-0.01%
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	0.00%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Alx Oncology Holdings	166.27 Mn	25.95 Mn	-	-

Download Data